ProfileGDS4814 / ILMN_2054261
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 49% 16% 62% 42% 32% 42% 20% 34% 41% 19% 47% 20% 27% 46% 34% 23% 10% 22% 42% 36% 51% 45% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)50.016549
GSM780708Untreated after 4 days (C2_1)42.771716
GSM780709Untreated after 4 days (C3_1)57.428662
GSM780719Untreated after 4 days (C1_2)48.259442
GSM780720Untreated after 4 days (C2_2)45.95932
GSM780721Untreated after 4 days (C3_2)48.279842
GSM780710Trastuzumab treated after 4 days (T1_1)43.643420
GSM780711Trastuzumab treated after 4 days (T2_1)46.459934
GSM780712Trastuzumab treated after 4 days (T3_1)48.010741
GSM780722Trastuzumab treated after 4 days (T1_2)43.416119
GSM780723Trastuzumab treated after 4 days (T2_2)49.648547
GSM780724Trastuzumab treated after 4 days (T3_2)43.49620
GSM780713Pertuzumab treated after 4 days (P1_1)45.068527
GSM780714Pertuzumab treated after 4 days (P2_1)49.390346
GSM780715Pertuzumab treated after 4 days (P3_1)46.487834
GSM780725Pertuzumab treated after 4 days (P1_2)44.199423
GSM780726Pertuzumab treated after 4 days (P2_2)41.15510
GSM780727Pertuzumab treated after 4 days (P3_2)44.015822
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)48.236342
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)46.797736
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)50.806251
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)48.931345
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)47.573839